Suppr超能文献

替加环素、头孢他啶/阿维巴坦和多黏菌素联合治疗产碳青霉烯酶菌血症:病例报告。

Aztreonam, Ceftazidime/Avibactam, and Colistin Combination for the Management of Carbapenemase-Producing Bacteremia: A Case Report.

机构信息

Department of Pharmacy, 23531Houston Methodist Sugarland Hospital, Sugar Land, TX, USA.

College of Pharmacy, 14743University of Houston, Houston, TX, USA.

出版信息

J Pharm Pract. 2021 Aug;34(4):653-657. doi: 10.1177/0897190019882262. Epub 2019 Nov 7.

Abstract

PURPOSE

A case of a patient with sepsis from a urinary source due to carbapenemase-producing treated with a novel combination of aztreonam, ceftazidime/avibactam, and colistin is described. An 80-year-old South Asian male presented to the hospital with sepsis from a urinary source. Blood and urine cultures were positive for a carbapenemase-producing sensitive only to colistin and tigecycline. Novel beta-lactamase inhibitor combinations ceftazidime/avibactam and meropenem/vaborbactam were resistant. Patient was initially on ceftazidime/avibactam and colistin combination followed by tigecycline and colistin with lack of improvement. Metallo-beta-lactamase (MBL)-producing was suspected based on the sensitivity pattern and history of medical treatment in India. Patient was then initiated on novel combination of ceftazidime/avibactam, aztreonam, and colistin. Patient's white blood cell (WBC) count and fever curve normalized. Unfortunately, the patient failed to recover completely likely because of his multiple comorbidities and declining functional status, resulting in the family's decision to pursue hospice.

CONCLUSION

The combination of ceftazidime/avibactam and aztreonam should be considered as a viable treatment option for patients with infections caused by MBL-producing Enterobacteriaceae.

摘要

目的

描述了一例由产碳青霉烯酶的尿路感染引起的败血症患者,该患者接受了新型组合药物治疗,包括氨曲南、头孢他啶/阿维巴坦和多黏菌素。一位 80 岁的南亚男性因尿路感染引起的败血症而入院。血液和尿液培养均对产碳青霉烯酶的细菌呈阳性,该细菌仅对多黏菌素和替加环素敏感。新型β-内酰胺酶抑制剂组合头孢他啶/阿维巴坦和美罗培南/沃巴坦耐药。患者最初接受头孢他啶/阿维巴坦和多黏菌素联合治疗,随后接受替加环素和多黏菌素治疗,但病情未见改善。根据药敏模式和在印度的治疗史,怀疑存在金属β-内酰胺酶(MBL)产生菌。随后,患者开始接受头孢他啶/阿维巴坦、氨曲南和多黏菌素的新型组合治疗。患者的白细胞(WBC)计数和发热曲线恢复正常。不幸的是,由于患者存在多种合并症和功能状态下降,未能完全康复,这导致患者家属决定寻求临终关怀。

结论

对于由 MBL 产生的肠杆菌科细菌感染患者,头孢他啶/阿维巴坦和氨曲南的联合治疗应被视为一种可行的治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验